Sugi Predict

Sugi Predict / Compounds / SCHEMBL10209059

SCHEMBL10209059

SCHEMBL10209059

CC(C)(C)OC(=O)CNCl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ DGAT1 O75907 1/20 0.38
▸ CYP2D6 P10635 1/20 0.37
▸ PTPRC P08575 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ MTNR1A P48039 1/20 0.33
▸ MTNR1B P49286 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23894059 0.80 CA2 (0.41) CA2CA12CA14DGAT1CYP2D6
SCHEMBL783009 0.80 CA2 (0.41) CA2CA12CA14DGAT1CYP2D6
SCHEMBL4943130 0.78 CA2 (0.40) CA2CA12CA14DGAT1CYP2D6
SCHEMBL410255 0.78 CA2 (0.40) CA2CA12CA14DGAT1CYP2D6
SCHEMBL6610608 0.78 MEN1 (0.41) CA2CA12CA14DGAT1CYP2D6
SCHEMBL10209390 0.77 EPHX2 (0.38) CA2CA12CA14DGAT1CYP2D6
SCHEMBL241533 0.76 DGAT1 (0.46) CA2CA12CA14DGAT1CYP2D6
SCHEMBL756932 0.76 CA2 (0.39) CA2CA12CA14DGAT1CYP2D6
SCHEMBL7660758 0.76 PTPRC (0.40) CA2CA12CA14DGAT1CYP2D6
SCHEMBL6535041 0.76 MAOA (0.44) CA2CA12CA14DGAT1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150946-A1 HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS OXFORD FINANCE LLC 2023-05-18 — — US disclosed
US-20230150946-A1 HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS OXFORD FINANCE LLC 2023-05-18 — — US disclosed
US-20230150946-A1 HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS OXFORD FINANCE LLC 2023-05-18 — — US disclosed
WO-2021178841-A1 HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS JANPIX, LTD. (US) 2021-09-10 — — WO disclosed
US-9592240-B2 Targeted pyrrolobenzodiazapine conjugates SEATTLE GENETICS INC. (US) 2017-03-14 — — US disclosed
US-9592240-B2 Targeted pyrrolobenzodiazapine conjugates SEATTLE GENETICS INC. (US) 2017-03-14 — — US disclosed
US-20160129013-A1 TARGETED PYRROLOBENZODIAZAPINE CONJUGATES SEAGEN INC. 2016-05-12 — — US disclosed
US-20160129013-A1 TARGETED PYRROLOBENZODIAZAPINE CONJUGATES SEAGEN INC. 2016-05-12 — — US disclosed
WO-2016045127-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 — — WO disclosed
WO-2016049099-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 — — WO disclosed
US-7960578-B2 Method for the synthesis of peptides without solvent CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2011-06-14 — — US disclosed
EP-2139910-B1 METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT CENTRE NAT RECH SCIENT (FR) 2011-05-25 — — EP disclosed
US-20100267686-A1 CARBACEPHEM BETA-LACTAM ANTIBIOTICS ACHAOGEN, INC. (US) 2010-10-21 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20100016631-A1 METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) 2010-01-21 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
WO-2008125418-A2 METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-10-23 — — WO disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150946-A1 HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS STAT5A, STAT5B, STAT3 CA2 4324/4885CA12 4517/4885CA14 4238/4885
US-20160129013-A1 TARGETED PYRROLOBENZODIAZAPINE CONJUGATES QDPR, SBDS, DNPEP CA2 3234/4885CA12 1059/4885CA14 543/4885
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 CA2 196/4885CA12 376/4885CA14 659/4885
US-20100267686-A1 CARBACEPHEM BETA-LACTAM ANTIBIOTICS MGAM, MGAM2, B2M CA2 670/4885CA12 278/4885CA14 880/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 CA2 196/4885CA12 376/4885CA14 659/4885
US-20100016631-A1 METHOD FOR THE SYNTHESIS OF PEPTIDES WITHOUT SOLVENT NRDC, NPPA, RTF1 CA2 2256/4885CA12 746/4885CA14 1158/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 CA2 196/4885CA12 376/4885CA14 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.